51-48-9
基本信息
O-(4-羟基-3,5-二碘苯基)-3,5-二碘-L-酪氨酸
2-甲状腺素
D-ALPHA-生育酚
左旋甲状腺素
L-Β-(3,5-二磺-4-羟基苯氧基)-3,5-二磺苯丙氨酸
左甲状腺素
甲狀腺素
3,5,3',5'-四碘甲[狀]腺胺酸
3,3\',5,5\'-四碘-L-甲腺原氨酸
(S)-O-(4-羟基-3,5-二碘苯基)-3,5-二碘酪氨酸,(S)-O-(4-HYDROXY-3,5-DIIODOPHENYL)-3,5-DIIODOTYROSINE
L-3,5,3',5'-四碘甲状腺原氨酸
甲四碘安,LEVOTHYROXINE
3,3',5,5'-TETRAIODO-L-THYRONINE
3,3',5,5'-TETRAIODO-L-THYRONINE SODIUM SALT
3,5,3',5'-TETRAIODO-L-THYRONINE
l-2-amino-3-[4-(4-hydroxy-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]-propanoic acid
LEVOTHYROXINE
LEVOTHYROXINE SODIUM
L-THYROXIN
L-THYROXINE
L-THYROXINE NA
L-THYROXINE SODIUM
L-THYROXINE SODIUM SALT
O-(4-HYDROXY-3,5-DIIODOPHENYL)-3,5-DIIODO-L-TYROSINE
(S)-2-AMINO-3-[4-(4-HYDROXY-3,5-DIIODOPHENOXY)-3,5-DIIODOPHENYL]PROPIONIC ACID
T4
TETRAIODOTHYRONINE, NA
THYROXINE
3,5,3’,5’-tetraiodothyronine
beta-[(3,5-diiodo-4-hydroxyphenoxy)-3,5-diiodophenyl]alanine
l-3,5,3’,5’-tetraiodothyronine
物理化学性质
| 外观性状 | 白色结晶。Mp235-236℃(分解)，比旋光度[α]20D-4.4°(3%，0.13 mol/L 氢氧化钠，70%乙醇)，在0.4 mol/L NaOH溶液中325nm波长处有最大吸收、0.4mol/L HCl溶液中295nm波长处有最大吸收。本品溶于碱溶液，不溶于水、乙醇和乙醚。 |
| 熔点 | 235 °C |
| 比旋光度 | -5 º (1N NaOH:EtOH 1:2) |
| 密度 | 2.4440 (estimate) |
| 闪点 | 9℃ |
| 储存条件 | 2-8°C |
| 溶解度 | 以50mg/ml溶于4M氢氧化铵的甲醇溶液 |
| 沸点 | 576.3±50.0 °C(Predicted) |
| 酸度系数(pKa) | 2.2(at 25℃) |
| 形态 | 粉末 |
| 颜色 | 白色至浅棕色 |
| 水溶解性 | insoluble |
| 敏感性 | 感光 |
| Merck | 9491 |
| BRN | 2228515 |
| InChIKey | XUIIKFGFIJCVMT-LBPRGKRZSA-N |
| CAS 数据库 | 51-48-9(CAS DataBase Reference) |
| EPA化学物质信息 | L-Thyroxine (51-48-9) |
安全数据
| 危险性符号(GHS) |    GHS02,GHS06,GHS08 |
| 警示词 | 危险 |
| 危险性描述 | H225-H301+H311+H331-H370 |
| 防范说明 | P210-P260-P280-P301+P310+P330-P302+P352+P312-P370+P378 |
| 危险品标志 | Xn,T,F |
| 危险类别码 | 40-39/23/24/25-23/24/25-11 |
| 安全说明 | S22-S24/25 |
| 危险品运输编号 | UN1230 - class 3 - PG 2 - Methanol, solution |
| WGK Germany | 3 |
| RTECS号 | YP2833500 |
| F | 8-10 |
| TSCA | Yes |
| 危险等级 | IRRITANT |
| 海关编码 | 29379000 |
| 毒害物质数据 | 51-48-9(Hazardous Substances Data) |
| 毒性 | TDLo oral in child: 328ug/kg |
应用领域
制备方法
L-甲状腺素价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/01/25 | HY-18341B | L-甲状腺素 L-Thyroxine sodium | 51-48-9 | 500mg | 650元 |
| 2024/01/25 | HY-18341B | L-甲状腺素 L-Thyroxine sodium | 51-48-9 | 10mM * 1mLin DMSO | 715元 |
| 2024/01/25 | HY-18341B | L-甲状腺素 L-Thyroxine sodium | 51-48-9 | 1g | 850元 |
常见问题列表
|
Human Endogenous Metabolite
|
Deiodinases (DIOs), which catalyse the conversion of thyroxine (pro-hormone) to the active thyroid hormone, are associated with thyroid stimulating hormone (TSH) levels. DIO1 and DIO2 catalyze activation of thyroid hormone secretion in contrast to DIO3 playing role inactivation of the secretion. Activities of DIO1 and DIO2 play pivotal role in the negative feedback regulation of pituitary TSH secretion. L-Thyroxine (T4) and Triiodothyronine (T3) hormones are known to modulate the expression of ionic channels, pumps and regulatory contractile proteins. Moreover, thyroid hormones have been shown to influence calcium homeostasis and flux responsible for excitation and contractility, with L-Thyroxine and Triiodothyronine modulating its pharmacological control and secretion. In rats fed 12 weeks with the iodine-free diet, a significant decrease in the levels of both Triiodothyronine and L-Thyroxine is observed when compared to the control group fed with standard diet (p<0.001). In the group treated with low doses of L-Thyroxine, an increase in L-Thyroxine levels is observed (p=0.02) while Triiodothyronine levels remain virtually similar to the control group (p=0.19). Rats treated with high doses of L-Thyroxine display a significant increase in both Triiodothyronine and L-Thyroxine circulating concentrations compared to the non-treated hypothyroid group (p<0.001 and p=0.004, respectively) and a significant increase in L-Thyroxine levels when compared to the control values (p=0.03).